Though ICI discontinued, patient No.4 experienced recurrent liver and kidney dysfunction after chemotherapy following irAE recovery, while one lung cancer patient successfully attempted EGFR targeted therapy after irAE recovery and achieved stable disease without dysfunction of liver and kidney. This evidence concerns the gene EGFR and lung carcinoma.